Establishing Practical Solutions for Cancer Patients through Precision Medicine Based on Bioinformatics Analysis
|關鍵字:||生物資訊;精準醫學;癌症;檢測;治療;膜蛋白;Bioinformatics;Precision Medicine;Cancer;Detection;Therapy;Membrane receptor|
Cancer is a disease which can be ascribed to progressive accumulation of genetic aberrations, and it has been the leading cause of death worldwide for decades. Many studies have indicated some critical mutations in cancers in the past decades. However, functional roles of these mutations are insufficient to fully explain the whole picture of oncogenesis. In order to comprehensively identify the potential mechanisms of oncogenesis, a number of studies investigated mutation patterns and gene expression profiling by high-throughput technology, e.g. microarray or next generation sequencing. From high-throughput data analysis, many genes with significantly alterations are recognized. Currently, cancers are typically classified by pathologic criteria that rely heavily on the tissue site of origin. Owing to recent progress in genomics and proteomics, the focus on individual genes and cellular components as disease loci and drug targets has been a necessary step in understanding the basic mechanisms underlying tissue/organ physiology and drug action. Precision medicine is a concept of diagnosis based on individual characteristics that may fall into a limited number of sets of characteristics resulting in the same pathophysiology and therapy. Precision medicine utilizes both conventional medicine and cutting edge technology to concur the disease proven to be resistant to conventional medical techniques. In this work, it is focused on identification of molecular biomarkers of female breast cancer for cancer panel design and for identification of cancer-overexpressed membrane receptors as putative targeting agents in cancer therapy. Mutation profiles of whole-exome sequencing data and gene expression profiles of RNA-seq data were collected from TCGA. Generally, 58 mutation biomarkers were identified for breast cancer panel design and tens of breast cancer-overexpressed membrane receptors were identified as candidates for production of new antibody drugs. In the future, it is expected that precision medicine is practical to every patient whose genomic information is known so that the analyzed results will be used to accurately determine his cancer subtype, the drug with the best therapeutic effect for prescription, and the best targeting agent for targeted delivery.
|Appears in Collections:||Thesis|